Understanding GAMMORA: Mechanism and Development
GAMMORA, a groundbreaking antiviral drug developed by Code Pharma, offers a novel approach to combating HIV. Clinical studies have shown that the drug functions by targeting and eliminating HIV-infected cells while promoting the regeneration of healthy CD4 cells. The drug introduces a peptide that induces an over-integration of viral DNA into the infected cells, effectively triggering their self-destruction. Unlike many treatments, GAMMORA leaves uninfected cells unharmed, making it a more precise and potentially less harmful option in the fight against HIV.
A Peptide-Based Solution by Code Pharma
GAMMORA is based on a 16-amino-acid peptide derived from HIV-1 integrase, an enzyme that HIV uses to insert its genetic material into host cells. The peptide’s unique mechanism was first discovered at the Hebrew University of Jerusalem in Israel, and it has since become the focus of Code Pharma’s research and development efforts.
The drug is currently undergoing rigorous testing, including in-vitro studies, animal trials, and human clinical trials, to ensure both its efficacy and safety. Researchers are optimistic about its potential to offer a more effective treatment compared to traditional HIV therapies. Code Pharma is also dedicated to ensuring that GAMMORA is user-friendly, aiming to create a treatment that patients can easily follow as part of their long-term health management. With its innovative approach, GAMMORA could represent a major breakthrough in the ongoing effort to treat and eventually eradicate HIV.